Seoul, South Korea and Nanjing, China – LG Chem Life Sciences (“LG Chem”), a division of LG Chem, and TransThera Biosciences jointly announce today the Investigational New Drug (IND) application of TT-01025 has been submitted to Food and Drug Administration (FDA) in the United States.
TT-01025 is a novel inhibitor of Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) for NASH. LG Chem reached an exclusive license agreement with TransThera Biosciences on August 17th, 2020 to research, develop, manufacture and commercialize TT-01025 in global region except Greater China and Japan.
Dr. Frank Wu, CEO of TransThera, commented, “Our collaboration program, TT-01025, has yielded an important milestone today. I congratulate both teams for advancing the project, with high quality, in an expedited and collaborative manner!”
“We are very pleased that the IND filing for TT-01025, an important first milestone, which is earlier than our planned timeline as a result of excellent collaboration. We’ve been preparing everything needed so that the Phase 1 clinical trial in the US would be initiated immediately upon the IND clearance.” commented Dr. Jeewoong Son, President of LG Chem Life Sciences.